Introduction
============

Recently, several large-scale studies have confirmed the effect of neoadjuvant chemotherapy (NAC) in the treatment of locally advanced gastric cancer (LAGC).[@b1-ott-11-7061],[@b2-ott-11-7061] The capecitabine and oxaliplatin (CAPOX) regimen is one of the recommended NACs.[@b3-ott-11-7061] The use of NAC has several potential benefits, including controlling micro-metastasis, increasing the chance of complete pathological response and the rate of R0 resection, and helping choose the postoperative regimen based on the pathological response.[@b4-ott-11-7061]

Researchers are continuously devoted to seeking predictors in gastric cancer (GC) patients who received NAC. It has been reported that lymph node stage, neural invasion, serum CA199 level, and resection type were associated with the disease-free survival (DFS) or overall survival (OS) of GC patients treated with NAC.[@b5-ott-11-7061] In addition, a growing body of studies investigating the influence of routine blood parameter ratios on prognosis have been published recently[@b6-ott-11-7061],[@b7-ott-11-7061] and there are several potential reasons for this intriguing trend: first, these ratios, such as the neutrophil-to-lymphocyte ratio (NLR),[@b6-ott-11-7061],[@b8-ott-11-7061] lymphocyte-to-monocyte ratio (LMR),[@b9-ott-11-7061] and platelet-to-lymphocyte ratio (PLR),[@b10-ott-11-7061] reflect the systemic inflammatory response[@b11-ott-11-7061] and emerging evidence indicates that inflammation plays a critical role in tumor initiation and progression[@b12-ott-11-7061],[@b13-ott-11-7061] and, second, routine blood results are easy to obtain and blood sampling is a safe procedure. Therefore, we think it necessary to investigate whether routine blood parameters and their ratios prior to chemotherapy can predict the efficacy of NAC in GC patients.

Patients and methods
====================

Patient selection
-----------------

One hundred and four eligible patients were enrolled from June 2010 to March 2016. The inclusion criteria for the study were as follows: 1) locally advanced gastric adenocarcinoma; 2) the CAPOX regimen as NAC; 3) gastrectomy with lymph node dissection and pathological evaluation for patients with no signs of disease progression, otherwise chemotherapy regimen would be changed; 4) Eastern Cooperative Oncology Group (ECOG) performance status ≤1; 5) available routine blood results before chemotherapy; 6) measurable tumor lesion or lymph node metastasis evaluated by multidetector spiral computed tomography (CT) scanning; and 7) no prior anticancer treatment. Tumors were staged according to the American Joint Committee on Cancer (AJCC) TNM stage classification, seventh edition, for GC.[@b14-ott-11-7061] The CAPOX regimen was delivered every 3 weeks: oxaliplatin (130 mg/m^2^) was administered by intravenous infusion over a period of 2 hours on day 1 and capecitabine (1,000 mg/m^2^) was administered orally twice daily from days 1 to 14. The ethics committee of Zhongshan Hospital Affiliated to Fudan University has approved this study, and the written informed consent was obtained from each patient before sample collection.

Follow-up
---------

After initiating CAPOX, each patient was followed up regularly until July 2017 or death. The follow-up periods varied from 5 to 83 months, with a median follow-up period of 25 months. Medical histories and physical examinations were obtained every cycle. CT scans were performed every two chemotherapy cycles before the operation and every 3 months after the operation. When severe toxic effects occurred,[@b15-ott-11-7061] the dosage of CAPOX was reduced by 25%--50%. The response to therapy was generally judged in the following two ways: through CT scans according to Response Evaluation Criteria in Solid Tumors (RECIST),[@b16-ott-11-7061] which defines a complete response (CR) and a partial response (PR) as objective responses, and through pathological evaluation using surgery specimens in accordance with the Sataloff method,[@b17-ott-11-7061] which defines tumor shrinkage greater than 50% as pathological remission and all other cases as no pathological remission. OS was calculated from diagnosis to death or the date of the last follow-up. Time to recurrence (TTR) was calculated from diagnosis to cancer recurrence, distant metastasis, or the last follow-up.

Blood sample analysis
---------------------

All peripheral blood samples were collected in tubes containing EDTA before chemotherapy. Blood cell counts, including white blood cell (WBC), granulocyte, lymphocyte, monocyte, red blood cell (RBC), blood platelet, and hemoglobin, were detected by a XT-1800i Automated Hematology System (Sysmex, Shanghai, China). The monocyte-to-WBC ratio (MWR), lymphocyte-to-WBC ratio (LWR), NLR, derived neutrophil-to-lymphocyte ratio (dNLR), PLR, and LMR were calculated from peripheral blood cell counts.

Statistical analysis
--------------------

The baseline routine blood results of eligible patients were presented as the median and range. The optimal cutoff levels of routine blood parameters, such as MWR, LWR, NLR, dNLR, PLR, and LMR, were determined by receiver operating curve (ROC) analysis.[@b18-ott-11-7061] The objective response rate (ORR) was applied to select the optimal cutoff points. The Chi-squared test or Fisher's exact test was used to compare the number of patients with an objective response or pathological remission between groups. Median OS or TTR and the corresponding 95% CI were calculated by Kaplan--Meier (K--M) survival analysis, and the significance was evaluated by the log-rank test. The predictors of objective response and pathological remission were determined by multivariate analysis using a logistic regression model, and the predictors of OS and TTR were evaluated by multivariate analysis using Cox's proportional hazards model. All statistical analyses were conducted using the SPSS 17.0 software (IBM Corporation, Armonk, NY, USA). *P*-values less than 0.05 indicated statistical significance.

Results
=======

The baseline characteristics of eligible patients
-------------------------------------------------

A total of 104 patients who were diagnosed with LAGC and received CAPOX as NAC were studied retrospectively in our hospital. Among these patients, there were 74 (71.2%) males and 30 (28.8%) females aged 31--78 years. According to Lauren's classification, the numbers of intestinal, mixed, and diffusal type carcinoma were 50 (48.1%), 20 (19.2%), and 34 (32.7%), respectively. Upon classification by tumor location, 29 (27.9%), 38 (36.5%), and 37 (35.6%) patients had tumors located at the cardia and fundus, angle and body, and antrum, respectively. Clinical tumor staging was based on the seventh edition of the AJCC TNM classification, and details are listed in [Table 1](#t1-ott-11-7061){ref-type="table"}. The median value and range of each baseline routine blood parameter among eligible patients are listed in [Table 2](#t2-ott-11-7061){ref-type="table"}.

Efficacy of chemotherapy and patient survival analysis
------------------------------------------------------

During the follow-up period, 82 (78.8%) patients achieved CR, PR, or stable disease (SD) by CT scans and subsequently underwent surgery, whereas 22 (21.2%) patients had local recurrence or distant metastasis. The median TTR and OS were 17.5 and 25.0 months, respectively. The 3-year recurrence-free survival rate and the OS rate were 37.8 and 42.9%, respectively. Among the patients who underwent surgery, 34 (41.5%) patients achieved pathological remission.

Patients with ≥50% of pathological remission had a much longer OS (*P*\<0.001) and TTR (*P*\<0.001). The median OS in patients with ≥50 and \<50% of pathological remission was 62.2 and 24.9 months, respectively. The median TTR in patients with ≥50 and \<50% of pathological remission was 62.6 and 19.8 months, respectively ([Table 3](#t3-ott-11-7061){ref-type="table"}). [Figure 1](#f1-ott-11-7061){ref-type="fig"} illustrates pathological sections from four patients: two patients (one intestinal type GC + one diffusal type GC) showed pathological remission and the other two patients (one intestinal type GC + one diffusal type GC) showed no pathological remission. In addition, the patients with CR, PR, or SD had longer OS and TTR. The patients with N downstaging after NAC also tended to have longer OS and TTR ([Table 3](#t3-ott-11-7061){ref-type="table"}). [Figure 2](#f2-ott-11-7061){ref-type="fig"} shows the K--M curves for OS or TTR according to pathological remission, objective response, and N downstaging.

The optimal cutoff levels for routine blood parameters and their ratios
-----------------------------------------------------------------------

Here, we calculated the optimal cutoff levels based on the objective response because the main purpose of this research was to identify the predictors for efficacy of the neoadjuvant CAPOX regimen. Through ROC curve analysis ([Figure 3](#f3-ott-11-7061){ref-type="fig"}), we obtained the optimal cutoff levels and areas under the curve (AUCs) of routine blood parameters and their ratios, as shown in [Table 4](#t4-ott-11-7061){ref-type="table"}. Patients were subsequently divided into two groups according to the cutoff value for each parameter.

Relationship between routine blood parameters and the efficacy of chemotherapy
------------------------------------------------------------------------------

As listed in [Table 5](#t5-ott-11-7061){ref-type="table"}, a higher lymphocyte count (≥1.750×10^9^/L), LWR (≥0.228), and LMR (≥4.583) and a lower platelet count (\<242.5×10^9^/L), dNLR (\<2.460), NLR (\<3.033), and PLR (\<130.7) were significantly associated with a higher ORR and pathological remission rate (pRR). In addition, a higher response rate was associated with a lower granulocyte count (\<4.450×10^9^/L) and a higher MWR (≥0.071) and hemoglobin level (≥137.5 g/L).

Relationship between routine blood parameters and patient survival time
-----------------------------------------------------------------------

Our results showed that the group with a lower lymphocyte count (\<1.750×10^9^/L) had a shorter OS and TTR. The median OS and TTR of patients with low lymphocyte level (\<1.750×10^9^/L) were 25.0 and 13.0 months, respectively. Meanwhile, a shorter TTR was observed in the group with a lower WBC count (\<5.695×10^9^/L) and a higher PLR (≥130.7). The median TTR of patients with a low WBC count (\<5.695×10^9^/L) and a high PLR (≥130.7) was 11.0 and 13.0 months, respectively ([Table 5](#t5-ott-11-7061){ref-type="table"}). In addition, K--M survival curves showing the differences in OS or TTR between patients with different routine blood parameter values and ratios are shown in [Figures 4](#f4-ott-11-7061){ref-type="fig"} and [5](#f5-ott-11-7061){ref-type="fig"}.

Independent predictors for the efficacy of chemotherapy in the multivariate analysis
------------------------------------------------------------------------------------

In the multivariate logistic regression analysis, a higher PLR (≥130.7) predicted a lower ORR (OR =5.927, 95% CI: 2.184--16.089) and pRR (OR =8.343, 95% CI: 2.178--31.962), while a higher LWR (≥0.228) independently predicted a higher ORR (OR =0.118, 95% CI: 0.031--0.448) and pRR (OR =0.096, 95% CI: 0.021--0.426). In addition, a higher monocyte count (≥0.215×10^9^/L) (OR =0.072, 95% CI: 0.008--0.636) and tumor located at the antrum (OR =0.154, 95% CI: 0.036--0.657) were another two independent predictors of a higher pRR ([Table 6](#t6-ott-11-7061){ref-type="table"}). The variables in the multivariate analysis were selected through univariate logistic regression analysis (*P*\<0.10) ([Table S1](#SD1-ott-11-7061){ref-type="supplementary-material"}).

Independent predictors of patient prognosis in the multivariate analysis
------------------------------------------------------------------------

Multivariate Cox regression analysis revealed that tumors located at the antrum (HR =0.433, 95% CI: 0.237--0.789), high lymphocyte count (≥1.750×10^9^/L) (HR =0.428, 95% CI: 0.190--0.964), and high monocyte count (≥0.215×10^9^/L) (HR =0.506, 95% CI: 0.257--0.997) were independent predictors of long OS, while regional lymph node metastasis (N3) (HR =1.680, 95% CI: 0.997--2.831) was an independent predictor of short OS. Independent factors that prolonged the TTR were tumor located at the antrum (HR =0.535, 95% CI: 0.309--0.927) and high lymphocyte count (≥1.750×10^9^/L) (HR =0.328, 95% CI: 0.156--0.690) ([Table 6](#t6-ott-11-7061){ref-type="table"}). The variables in the multivariate analysis were selected through univariate Cox regression analysis (*P*\<0.10) ([Table S1](#SD1-ott-11-7061){ref-type="supplementary-material"}).

Discussion
==========

The relationship between preoperative NLR, PLR, or LMR and prognosis in GC patients has been discussed at great lengths; however, the association of these ratios with chemotherapeutic efficacy has seldom been discussed.[@b9-ott-11-7061],[@b10-ott-11-7061] Notwithstanding the model of perioperative chemotherapy with surgery that has almost become a consensus in LAGC recently,[@b3-ott-11-7061] few people have investigated the value of routine blood parameters in predicting the efficacy of chemotherapy or the prognosis of patients in a neoadjuvant setting; thus, we tried to ascertain whether these parameters and their ratios would be applicable and useful in GC patients treated with the neoadjuvant CAPOX regimen.

According to the results of our multivariate analysis, a high PLR (≥130.7) was an independent predictor of poor efficacy when patients were treated with neoadjuvant CAPOX regimen, as evidenced by the ORR and pRR analyses. In addition, the negative effect of a high PLR on GC patient prognosis was supported by data from several studies: a meta-analysis published in 2015 demonstrated a higher risk of short OS in GC patients with a high PLR.[@b19-ott-11-7061]

The association of a high PLR with low chemotherapeutic efficacy or poor prognosis could result from an elevated platelet count or a decreased lymphocyte count. Activated platelets created a procoagulant microenvironment that enabled tumor cells to cover themselves with platelets and evaded the host immune system.[@b20-ott-11-7061] Through aggregation, degranulation, and the consequent release of different types of factors, platelets contributed to chemoresistance by immunosuppression and induction of epithelial--mesenchymal transition (EMT) in GC. For example, platelet-derived transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) was often investigated in this context. 5-Fluorouracil-resistant GC cells displayed mesenchymal characteristics, and over-expression of TGF-β receptor 2 (TGFBR2) could decrease 5-fluorouracil sensitivity of GC cells.[@b21-ott-11-7061] Besides, TGF-β1 was shown to promote immune tolerance in GC cell lines by inducing regulatory T cells[@b22-ott-11-7061] and immunosuppressive macrophages.[@b23-ott-11-7061] VEGF-C mediated GC cell metastasis and cisplatin resistance, while VEGF-C-targeted microRNA-101 could reverse the resistance through inducing apoptosis.[@b24-ott-11-7061]

For lymphocytes, which played a large role in cancer immunosurveillance,[@b25-ott-11-7061] the decrease of both count and function indicated the suppression of antitumor responses[@b26-ott-11-7061] and might be caused by the inhibition of neutrophils surrounding the tumor.[@b27-ott-11-7061] Our results showed that a high lymphocyte level independently predicted a long OS and TTR. However, the different subsets of lymphocytes actually played quite different, even opposite roles in the tumor immunity of GC. Our team published one study in 2017, which showed that the reduction in CD19^+^ CD24hCD27^+^ B cell in peripheral blood predicted favorable outcome in CAPOX-treated patients with advanced GC.[@b28-ott-11-7061] As for the expression of CD4^+^ T, CD8^+^ T, Treg, and Th17 cells in GC patients' peripheral blood, we only found that the percentage of high CD3^+^ CD8^+^ lymphocytes and low Tregs were strongly associated with response to chemotherapy and the prognosis of GC. Neither CD3^+^ T cells nor CD3^+^ CD4^+^ T cells showed significant changes after chemotherapy or correlations with the clinical course.[@b29-ott-11-7061]

In the multivariate analysis, high monocyte level independently predicted high pRR and long OS. It was well-known that tumor-associated macrophages (TAMs) mainly derived from circulating monocytes and could be divided into two phenotypic subtypes. One type was tumoricidal M1 macrophage producing proinflammatory cytokines, chemokines, and reactive nitrogen/oxygen intermediates. Another type was tumor-promoting M2 macrophage induced by immunoregulatory cytokines such as interleukin (IL)-10 and IL-13.[@b30-ott-11-7061],[@b31-ott-11-7061] As TAMs were more closely linked to M2-type macrophages rather than M1-type macrophages, many studies have shown that high levels of TAMs were associated with poor clinical outcome by promoting invasion, metastasis, and angiogenesis.[@b32-ott-11-7061] However, conflicting results also have been reported that TAMs were independent good prognostic factors in GC.[@b33-ott-11-7061] There were also researches showing that TAMs in GCs had no significant association with OS.[@b34-ott-11-7061] Perhaps further studies focusing on the specific role of each TAMs' subset (M1 and M2) in GCs would be needed.

High NLR, PLR, and the changes in these parameters after one cycle of chemotherapy have been reported to be independent prognostic factors for poor OS in patients with advanced GC receiving palliative FOLFOX (5-fluorouracil with calcium folinate and oxaliplatin) regimen.[@b6-ott-11-7061] Another article reported that short OS and progression-free survival (PFS) were independently associated with a high NLR in patients with LAGC receiving the neoadjuvant FOLFOX regimen.[@b35-ott-11-7061] Both of these studies focused on the FOLFOX regimen, while our research focused on the CAPOX regimen, and our multivariate analysis did not reveal a significant association between the prognosis and NLR or PLR as those articles did. However, we discovered that high PLR level was an independent predictor for poor efficacy of the neoadjuvant CAPOX regimen. Furthermore, we included only the CAPOX regimen as NAC for advanced GC; thus, bias from different chemotherapy regimens was avoided. The pRR classified by the Sataloff method has not often been utilized in previous studies investigating GC patients. We discovered that the Sataloff method was a very effective way of evaluating the pathological response in GC patients (especially those in stage III) receiving NAC.

There was still a limitation that we should point out here. As a retrospective study, we did not gather the comprehensive data of immunocellular subsets' counts (such as CD4^+^/CD8^+^ T cells, CD19^+^ B cells, and CD68^+^ monocytes) in peripheral blood. The analysis of these subsets would probably provide us with more insight into the cross-talk between GC cells, tumor microenvironment, and immune cells. We considered that it would be meaningful to conduct such analysis in future researches.

Conclusion
==========

For patients with LAGC who received the neoadjuvant CAPOX regimen, we identified prechemotherapy routine blood results that were closely associated with chemotherapeutic efficacy and prognosis. A high PLR (≥130.7) predicted a low ORR and pRR, while a high LWR (≥0.228) independently predicted a high ORR and pRR. A high lymphocyte level (≥1.750×10^9^/L) was an independent predictor of long OS and TTR, while a high monocyte level (≥0.215×10^9^/L) was an independent predictor of a high pRR and long OS. Therefore, large, randomized, and prospective studies will be designed to determine the significance of routine blood results on the efficacy of NAC for LAGC patients and the mechanism by which WBCs interact with the tumor microenvironment deserves further study.

Supplementary material
======================

###### 

Univariate analysis investigating predictors for objective response rate, pathological remission rate, overall survival, and time to recurrence

  Variables                                  Objective response   Pathological remission   Overall survival   Time to recurrence                               
  ------------------------------------------ -------------------- ------------------------ ------------------ -------------------- ------- ----------- ------- -----------
  Gender (female)                            0.992                0.986                    3.057              **0.038**            1.600   **0.077**   1.408   0.186
  Age (≥65 years)                            0.769                0.522                    0.548              0.189                0.740   0.252       0.749   0.257
  WBC (≥5.695×10^9^/L)                       1.821                0.150                    1.035              0.939                0.627   **0.082**   0.562   **0.025**
  GRAN (≥4.450×10^9^/L)                      4.024                **0.010**                2.800              **0.056**            0.940   0.837       0.793   0.419
  LYMPHO (≥1.750×10^9^/L)                    0.242                **0.004**                0.253              **0.008**            0.386   **0.018**   0.340   **0.004**
  MONO (≥0.215×10^9^/L)                      0.588                0.395                    0.238              **0.076**            0.556   **0.072**   0.603   0.115
  RBC (≥4.480×10^12^/L)                      0.532                0.147                    0.714              0.468                0.946   0.851       0.828   0.495
  PLT (≥242.5×10^9^/L)                       5.000                **0.001**                3.019              **0.023**            0.914   0.736       1.072   0.782
  HGB (≥137.5 g/L)                           0.217                **0.006**                0.343              **0.063**            0.659   0.301       0.478   **0.065**
  LMR (≥4.583)                               0.307                **0.012**                0.326              **0.016**            0.934   0.824       0.741   0.321
  NLR (≥3.033)                               12.396               \<**0.001**              12.212             \<**0.001**          1.110   0.698       0.994   0.981
  PLR (≥130.7)                               9.615                \<**0.001**              10.738             \<**0.001**          1.536   0.122       1.759   **0.038**
  MWR (≥0.071)                               0.420                **0.038**                0.563              0.211                0.763   0.323       0.932   0.780
  LWR (≥0.228)                               0.071                \<**0.001**              0.075              \<**0.001**          0.721   0.220       0.886   0.634
  dNLR (≥2.460)                              7.583                **0.002**                4.113              **0.021**            0.981   0.947       0.918   0.761
  Lauren classification (mixed + diffused)   0.956                0.913                    0.920              0.853                1.386   0.210       1.256   0.359
  Tumor location (antrum)                    0.642                0.293                    0.455              **0.089**            0.519   **0.025**   0.588   **0.052**
  Depth of invasion (T4)                     \<0.001              0.999                    \<0.001            0.999                0.242   **0.008**   0.211   **0.004**
  Regional lymph node metastasis (N3)        0.943                0.891                    0.676              0.439                1.636   **0.064**   1.650   **0.050**
  Tumor staging (IIIc)                       0.920                0.845                    0.847              0.742                1.309   0.314       1.313   0.291

**Note:** The bold *P*-values \<0.10 means the difference is statistically significant.

**Abbreviations:** dNLR, derived NLR; GRAN, granulocyte; HGB, hemoglobin; LMR, LYMPHO-to-MONO ratio; LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; NLR, neutrophil-to-LYMPHO ratio; RBC, red blood cell; PLR, PLT-to-LYMPHO ratio; PLT, platelet; WBC, white blood cell.
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![H&E HE staining (5× and 10×) of four patients' pathological section.\
**Notes:** (**A**) H&E HE staining of a patient with intestinal type GC, which showed no pathological remission. (**B**) H&E HE staining of a patient with difussal type GC, which showed no pathological remission. (**C**) H&E HE staining of a patient with intestinal type GC, which showed pathological remission. (**D**) H&E HE staining of a patient with diffusal type GC, which showed pathological remission.\
**Abbreviation:** GC, gastric cancer.](ott-11-7061Fig1){#f1-ott-11-7061}

![K--M curves for OS or TTR according to blood pathological remission, objective response, or N downstaging.\
**Notes:** (**A**) OS according to pathological remission. (**B**) TTR according to pathological remission. (**C**) OS according to objective response. (**D**) TTR according to objective response. (**E**) OS according to N downstaging. (**F**) TTR according to N downstaging. N downstaging was defined as lymph node downstaging when comparing ypTNM with cTNM according to AJCC TNM stage classification for gastric cancer (seventh edition).\
**Abbreviations:** AJCC, American Joint Committee on Cancer; CR, complete response; K--M, Kaplan--Meier; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease; TTR, time to recurrence.](ott-11-7061Fig2){#f2-ott-11-7061}

![ROC curves indicating cutoff levels of blood routine parameters and the ratios based on blood routine results.\
**Notes:** (**A**) ROC curves for WBC, GRAN, and PLT. (**B**) ROC curves for RBC, MONO, LYMPHO, and HGB. (**C**) ROC curves for PLR, NLR, and dNLR. (**D**) ROC curves for LWR, MWR, and LMR.\
**Abbreviations:** dNLR, derived NLR; GRAN, granulocyte; HGB, hemoglobin; LMR, LYMPHO-to-MONO ratio; LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; NLR, neutrophil-to-LYMPHO ratio; PLR, PLT-to-LYMPHO ratio; PLT, platelet; RBC, red blood cell; ROC, receiver operating curve; WBC, white blood cell.](ott-11-7061Fig3){#f3-ott-11-7061}

![K--M curves for OS or TTR according to blood routine parameters.\
**Notes:** (**A**) OS according to WBC level. (**B**) TTR according to WBC level. (**C**) OS according to GRAN level. (**D**) TTR according to GRAN level. (**E**) OS according to LYMPHO level. (**F**) TTR according to LYMPHO level. (**G**) OS according to MONO level. (**H**) TTR according to MONO level. (**I**) OS according to RBC level. (**J**) TTR according to RBC level. (**K**) OS according to PLT level. (**L**) TTR according to PLT level. (**M**) OS according to HGB level. (**N**) TTR according to HGB level.\
**Abbreviations:** GRAN, granulocyte; HGB, hemoglobin; K--M, Kaplan--Meier; LYMPHO, lymphocyte; MONO, monocyte; OS, overall survival; PLT, platelet; RBC, red blood cell; TTR, time to recurrence; WBC, white blood cell.](ott-11-7061Fig4){#f4-ott-11-7061}

![K--M curves for OS or TTR according to ratios based on blood routine results.\
**Notes:** (**A**) OS according to NLR level. (**B**) TTR according to NLR level. (**C**) OS according to PLR level. (**D**) TTR according to PLR level. (**E**) OS according to LWR level. (**F**) TTR according to LWR level. (**G**) OS according to dNLR level. (**H**) TTR according to dNLR level. (**I**) OS according to MWR level. (**J**) TTR according to MWR level. (**K**) OS according to LMR level. (**L**) TTR according to LMR level.\
**Abbreviations:** dNLR, derived NLR; K--M, Kaplan--Meier; LMR, lymphocyte-to-monocyte ratio; LWR, lymphocyte-to-WBC ratio; MWR, monocyte-to-WBC ratio; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; TTR, time to recurrence.](ott-11-7061Fig5){#f5-ott-11-7061}

###### 

Baseline clinicopathological characteristics of eligible patients

  Characteristics                                                             Total, n (%)
  --------------------------------------------------------------------------- --------------
                                                                              
  Gender                                                                      
   Female                                                                     30 (28.8)
   Male                                                                       74 (71.2)
                                                                              
  Age (years)                                                                 
   \<65                                                                       59 (56.7)
   ≥65                                                                        45 (43.3)
                                                                              
  Lauren classification                                                       
   Intestinal                                                                 50 (48.1)
   Mixed                                                                      20 (19.2)
   Diffusal                                                                   34 (32.7)
                                                                              
  Tumor location                                                              
   Cardia and fundus                                                          29 (27.9)
   Angle and body                                                             38 (36.5)
   Antrum                                                                     37 (35.6)
                                                                              
  Depth of invasion[a](#tfn1-ott-11-7061){ref-type="table-fn"}                
   T3                                                                         4 (3.8)
   T4                                                                         100 (96.2)
                                                                              
  Regional lymph node metastasis[a](#tfn1-ott-11-7061){ref-type="table-fn"}   
   N1                                                                         32 (30.8)
   N2                                                                         31 (29.8)
   N3                                                                         36 (34.6)
   Nx                                                                         5 (4.8)
                                                                              
  Clinical tumor staging[a](#tfn1-ott-11-7061){ref-type="table-fn"}           
   IIb                                                                        3 (3.0)
   IIIa                                                                       28 (27.7)
   IIIb                                                                       34 (33.7)
   IIIc                                                                       36 (35.6)

**Notes:**

cTNM based on the seventh edition of AJCC TNM classification.

**Abbreviation:** AJCC, American Joint Committee on Cancer.

###### 

The median value of baseline routine blood results of patients

  Characteristics     Median values   Range
  ------------------- --------------- ---------------
                                      
  WBC (×10^9^/L)      5.60            2.96--11.30
  GRAN (×10^9^/L)     3.60            0.70--8.50
  LYMPHO (×10^9^/L)   1.35            0.20--3.70
  MONO (×10^9^/L)     0.40            0.20--1.06
  RBC (×10^12^/L)     4.05            2.17--5.53
  PLT (×10^9^/L)      219.5           82.0--450.0
  HGB (g/L)           115.5           51.0--158.0
  MWR                 0.067           0.038--0.310
  LWR                 0.250           0.022--0.521
  NLR                 2.624           0.429--42.000
  dNLR                1.891           0.257--12.000
  PLR                 158.2           54.7--505.6
  L MR                3.750           0.500--9.250

**Abbreviations:** dNLR, derived NLR; GRAN, granulocyte; HGB, hemoglobin; LMR, LYMPHO-to-MONO ratio; LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; NLR, neutrophil-to-LYMPHO ratio; PLR, PLT-to-LYMPHO ratio; PLT, platelet; RBC, red blood cell; WBC, white blood cell.

###### 

Survival analysis of eligible patients

  Indexes of survival analysis   Classification             Median OS (95% CI) (months)   *P*-value           Median TTR (95% CI) (months)   *P*-value
  ------------------------------ -------------------------- ----------------------------- ------------------- ------------------------------ -----------
                                                                                                                                             
  Pathological remission         ≥50% of remission (n=34)   62.2 (49.9, 74.5)             \<0.001             62.6 (51.2, 74.0)              \<0.001
  \<50% of remission (n=70)      24.9 (20.7, 29.1)                                        19.8 (14.8, 24.8)                                  
                                                                                                                                             
  Objective response             CR + PR + SD (n=82)        44.8 (36.8, 52.8)             \<0.001             43.6 (35.5, 51.8)              \<0.001
  PD (n=22)                      17.7 (13.6, 21.9)                                        8.0 (5.9, 10.2)                                    
                                                                                                                                             
  N downstaging                  N downstaging (+) (n=37)   56.3 (45.3, 67.4)             \<0.001             54.6 (43.1, 66.0)              \<0.001
  N downstaging (−) (n=67)       24.9 (21.2, 28.6)                                        19.0 (14.8, 23.1)                                  

**Notes:** N downstaging was defined as lymph node downstaging when comparing ypTNM with cTNM according to AJCC TNM stage classification for gastric cancer (seventh edition).

**Abbreviations:** AJCC, American Joint Committee on Cancer; CR, complete response; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease; TTR, time to recurrence.

###### 

Optimal cutoff value together with AUCs based on objective response evaluation

  Variables   Objective response   
  ----------- -------------------- ----------------
                                   
  RBC         0.552                4.480×10^12^/L
  PLT         0.664                242.5×10^9^/L
  HGB         0.593                137.5 g/L
  WBC         0.563                5.695×10^9^/L
  GRAN        0.594                4.450×10^9^/L
  LYMPHO      0.716                1.750×10^9^/L
  MONO        0.506                0.215×10^9^/L
  dNLR        0.637                2.460
  LWR         0.759                0.228
  LMR         0.637                4.583
  MWR         0.567                0.071
  PLR         0.778                130.7
  NLR         0.736                3.033

**Abbreviations:** AUCs, areas under the curve; dNLR, derived NLR; GRAN, granulocyte; HGB, hemoglobin; LMR, LYMPHO-to-MONO ratio; LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; NLR, neutrophil-to-LYMPHO ratio; PLR, PLT-to-LYMPHO ratio; PLT, platelet; RBC, red blood cell; WBC, white blood cell.

###### 

Analysis of objective response, pathological remission, OS, or TTR in patients according to cutoff values

  Characteristics   Classification     Number (%) of patients with objective response   *P*~1~        Number (%) of patients with pathological remission   *P*~2~        Median OS (95% CI) (months)   *P*~3~      Median TTR (95% CI) (months)   *P*~4~
  ----------------- ------------------ ------------------------------------------------ ------------- ---------------------------------------------------- ------------- ----------------------------- ----------- ------------------------------ -----------
                                                                                                                                                                                                                                                  
  WBC               \<5.695×10^9^/L    24 (42.9)                                        0.148         18 (41.9)                                            0.939         21.0 (13.2--28.8)             0.076       11.0 (6.1--15.9)               **0.021**
                    ≥5.695×10^9^/L     14 (29.2)                                                      16 (41.0)                                                          44.0 (26.9--69.1)                         30.0                           
  GRAN              \<4.450×10^9^/L    33 (44.6)                                        **0.007**     28 (48.3)                                            0.052         32.0 (20.4--43.6)             0.835       16.0 (9.7--22.3)               0.410
                    ≥4.450×10^9^/L     5 (16.7)                                                       6 (25.0)                                                           27.0 (15.6--38.3)                         23.0 (9.4--36.6)               
  LYMPHO            \<1.750×10^9^/L    23 (28.7)                                        **0.003**     19 (32.2)                                            **0.006**     25.0 (16.8--33.2)             **0.013**   13.0 (7.2--18.8)               **0.002**
                    ≥1.750×10^9^/L     15 (62.5)                                                      15 (65.2)                                                          Not reached                               Not reached                    
  MONO              \<0.215×10^9^/L    4 (26.7)                                         0.391         2 (16.7)                                             0.059         19.0 (16.5--21.5)             0.065       11.0 (4.7--17.3)               0.104
                    ≥0.215×10^9^/L     34 (38.2)                                                      32 (45.7)                                                          33.0 (19.1--46.9)                         20.0 (11.4--28.5)              
  RBC               \<4.480×10^12^/L   23 (31.9)                                        0.144         20 (38.5)                                            0.468         27.0 (16.6--37.3)             0.849       17.0 (7.8--26.2)               0.486
                    ≥4.480×10^12^/L    15 (46.9)                                                      14 (46.7)                                                          32.0 (21.8--42.2)                         18.0 (10.5--25.5)              
  PLT               \<242.5×10^9^/L    31 (50.0)                                        **0.001**     25 (52.1)                                            **0.020**     32.0 (20.9--43.1)             0.733       17.0 (11.6--22.4)              0.778
                    ≥242.5×10^9^/L     7 (16.7)                                                       9 (26.5)                                                           28.0 (17.3--38.7)                         19.0 (9.5--28.5)               
  HGB               \<137.5 g/L        26 (30.2)                                        **0.004**     24 (36.4)                                            0.057         27.0 (17.1--36.9)             0.291       16.0 (9.7--22.3)               0.054
                    ≥137.5 g/L         12 (66.7)                                                      10 (62.5)                                                          32.0                                      Not reached                    
  LMR               \<4.583            22 (28.6)                                        **0.004**     20 (34.5)                                            **0.046**     28.0 (21.0--35.0)             0.822       18.0 (13.8--22.2)              0.310
                    ≥4.583             16 (59.3)                                                      14 (58.3)                                                          34.0                                      22.0                           
  NLR               \<3.033            35 (52.3)                                        \<**0.001**   31 (58.5)                                            \<**0.001**   32.0 (18.4--45.6)             0.694       17.0 (9.2--24.8)               0.980
                    ≥3.033             3 (8.1)                                                        3 (10.3)                                                           27.0 (22.0--32.0)                         19.0 (11.0--27.0)              
  PLR               \<130.7            25 (69.4)                                        \<**0.001**   22 (75.9)                                            \<**0.001**   36.0 (23.9--48.1)             0.115       37.0 (9.4--64.6)               **0.033**
                    ≥130.7             13 (19.1)                                                      12 (22.6)                                                          26.0 (18.0--34.0)                         13.0 (7.3--18.7)               
  MWR               \<0.071            18 (28.6)                                        **0.036**     18 (36.0)                                            0.209         27.0 (22.6--31.4)             0.315       17.0 (9.4--24.6)               0.775
                    ≥0.071             20 (48.8)                                                      16 (50.0)                                                          33.0 (17.1--48.9)                         20.0 (9.1--30.9)               
  LWR               \<0.228            3 (7.7)                                          \<**0.001**   3 (10.0)                                             \<**0.001**   27.0 (19.3--34.7)             0.212       17.0 (7.9--26.1)               0.627
                    ≥0.228             30 (46.2)                                                      31 (59.6)                                                          34.0 (21.6--46.4)                         19.0 (11.5--26.5)              
  dNLR              \<2.460            35 (46.7)                                        **0.001**     30 (49.2)                                            **0.016**     32.0 (23.2--40.8)             0.946       17.0 (10.6--23.4)              0.756
                    ≥2.460             3 (10.4)                                                       4 (19.0)                                                           28.0 (9.7--46.3)                          19.0 (7.3--30.7)               

**Notes:** *P*~1~ and *P*~2~, difference between two groups was tested by Chi-squared test. *P*~3~ and *P*~4~, difference between two groups was tested by Log-rank test. Not reached, less than half of the patients in the group were censored upon the latest follow-up. The bold *P*-values \<0.05 means the difference is statistically significant.

**Abbreviations:** dNLR, derived NLR; GRAN, granulocyte; HGB, hemoglobin; LMR, LYMPHO-to-MONO ratio; LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; NLR, neutrophil-to-LYMPHO ratio; OS, overall survival; PLR, PLT-to-LYMPHO ratio; PLT, platelet; RBC, red blood cell; TTR, time to recurrence; WBC, white blood cell.

###### 

Predictors for objective response rate, pathological remission rate, OS, and time to recurrence in multivariate analysis

  Variables                             Objective response      Pathological remission   OS                      Time to recurrence                                                         
  ------------------------------------- ----------------------- ------------------------ ----------------------- -------------------- ---------------------- ------- ---------------------- -------
                                                                                                                                                                                            
  LYMPHO (≥1.750×10^9^/L)                                                                                                             0.428 (0.190--0.964)   0.040   0.328 (0.156--0.690)   0.003
  MONO (≥0.215×10^9^/L)                                                                  0.072 (0.008--0.636)    0.018                0.506 (0.257--0.997)   0.049                          
  PLR (≥130.7)                          5.927 (2.184--16.089)   \>0.001                  8.343 (2.178--31.962)   0.002                                                                      
  LWR (≥0.228)                          0.118 (0.031--0.448)    0.002                    0.096 (0.021--0.426)    0.002                                                                      
  Tumor location (antrum)                                                                0.154 (0.036--0.657)    0.012                0.433 (0.237--0.789)   0.006   0.535 (0.309--0.927)   0.026
  Regional lymph node metastasis (N3)                                                                                                 1.680 (0.997--2.831)   0.051                          

**Abbreviations:** LWR, LYMPHO-to-WBC ratio; LYMPHO, lymphocyte; MONO, monocyte; MWR, MONO-to-WBC ratio; OS, overall survival; PLR, PLT-to-LYMPHO ratio; WBC, white blood cell; PLT, platelet.
